ONCOLOGY: March 2010 Volume 24 Number 3 Supplement 2

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.